Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details)

v3.19.3
Basis of Presentation and Summary of Significant Accounting Policies - Revenue by Source (Details) - USD ($)
$ in Thousands
2 Months Ended 3 Months Ended 9 Months Ended
Mar. 06, 2019
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Disaggregation of Revenue [Line Items]          
Total revenue   $ 24,808 $ 45,663 $ 93,279 $ 191,863
Royalties          
Disaggregation of Revenue [Line Items]          
Total revenue   9,767 36,127 35,931 88,343
Promacta          
Disaggregation of Revenue [Line Items]          
Total revenue $ 14,200 0 27,812 14,193 68,191
Kyprolis          
Disaggregation of Revenue [Line Items]          
Total revenue   7,602 6,286 16,317 14,411
Evomela          
Disaggregation of Revenue [Line Items]          
Total revenue   1,515 1,356 3,570 4,116
Other          
Disaggregation of Revenue [Line Items]          
Total revenue   650 673 1,851 1,625
Material Sales: Captisol          
Disaggregation of Revenue [Line Items]          
Total revenue   6,849 7,027 24,357 19,030
License fees, milestones and other          
Disaggregation of Revenue [Line Items]          
Total revenue   8,192 2,509 32,991 84,490
License Fees          
Disaggregation of Revenue [Line Items]          
Total revenue   243 265 3,083 75,201
Milestone          
Disaggregation of Revenue [Line Items]          
Total revenue   4,790 1,308 20,897 6,052
Other          
Disaggregation of Revenue [Line Items]          
Total revenue   $ 3,159 $ 936 $ 9,011 $ 3,237